Bacterial Membrane Coating Potentiates Lipid Nanoparticles for mRNA Delivery
- 24 November 2025
- journal article
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 25 (49) , 17074-17081
Abstract
Bacterial outer membrane vesicles (OMVs) possess intrinsic immunostimulatory properties by carrying native antigens and pathogen-associated molecular patterns (PAMPs). Lipid nanoparticles (LNPs) have become the leading platform for messenger ribonucleic acid (mRNA) delivery, underpinning the clinical success of mRNA vaccines. Here, we developed a hybrid nanoparticle formulation, OMV-coated LNPs (OMV-LNPs), that combines the high delivery efficiency of LNPs with the immunogenicity of the OMVs to enhance gene delivery. Using Escherichia coli-derived OMVs and dengue virus (DENV) E80 protein as a model antigen, we generated OMV-LNPs encapsulating DENV mRNA (OMV-LNPmRNA). These nanoparticles demonstrated improved uptake by lymph-node-resident immune cells and enhanced cytosolic mRNA delivery, resulting in robust dendritic cell maturation and proinflammatory cytokine production in vitro. In AG129 mice, the OMV-LNPmRNA elicited significantly higher titers of DENV-neutralizing antibodies compared to conventional LNPs. Collectively, these results establish OMV-LNPs as a versatile and potent platform for effective mRNA vaccine delivery.Keywords
Funding Information
- Defense Threat Reduction Agency (HDTRA1-21-1-0010)
This publication has 31 references indexed in Scilit:
- mRNA-based therapeutics: looking beyond COVID-19 vaccinesThe Lancet, 2024
- Dendritic Cell‐Mimicking Nanoparticles Promote mRNA Delivery to Lymphoid OrgansAdvanced Science, 2023
- Genetically engineered cellular nanoparticles for biomedical applicationsBiomaterials, 2023
- Outer Membrane Vesicle‐Coated Nanoparticle Vaccine Protects against Acinetobacter baumannii Pneumonia and SepsisAdvanced NanoBiomed Research, 2022
- Rapid Surface Display of mRNA Antigens by Bacteria‐Derived Outer Membrane Vesicles for a Personalized Tumor VaccineAdvanced Materials, 2022
- Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective studyThe Lancet Regional Health - Europe, 2021
- Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in MiceMolecular Therapy - Methods & Clinical Development, 2020
- Cell Membrane Coating NanotechnologyAdvanced Materials, 2018
- Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequenceVaccine, 2017
- Bacterial membrane proteomicsProteomics, 2008